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Risk Classiﬁcation With Gated Stress Myocardial
Perfusion SPECT
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Robert C. Hendel, MD,‡ Salvador Borges-Neto, MD,§ Daniel S. Berman, MD
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and Los Angeles, California
O B J E C T I V E S We compared analytical approaches to estimate the added value of myocardial
perfusion single-photon emission computed tomography (MPS) variables in estimating coronary artery
disease (CAD) outcomes.
B A C KG ROUND Stress MPS markers of regional ischemia are strong estimators of prognosis.
Evidence published to date has not compared analytical methods to establish the added value of stress
MPS and to deﬁne a clinically meaningful approach to detect improve classiﬁcation of risk.
METHOD S A total of 4,575 patients were consecutively and prospectively enrolled in the Myoview
Prognosis Registry. Multivariable Cox proportional hazards model were employed to estimate CAD death
or myocardial infarction (MI). Risk reclassiﬁcation methods were also calculated.
R E S U L T S In risk-adjusted models (including age, sex, presenting symptoms, stress type, CAD history,
and risk factors), stress MPS ischemia, rest and post-stress left ventricular ejection fraction (LVEF) (all p 
0.0001) were all signiﬁcant estimators of CAD death or MI. In this multivariable model, 34% of the model
chi-square was contributed by MPS ischemia. In receiver-operating characteristic curve analysis, the area
under the curve increased from 0.61 to 0.66 when rest and post-stress LVEF were combinedwith pre-test CAD
likelihood (p  0.0001), increasing to 0.69 for MPS ischemia (p  0.0001). The net reclassiﬁcation
improvement (NRI) by adding the Duke Treadmill Score (DTS) to a model including pre-test CAD likelihood
was 0.112. The cost per NRI was $57 for the exercise test as compared with an ofﬁce visit for risk stratiﬁcation
purposes. Further, the NRI by adding MPS ischemia to a model with the DTS and pre-test CAD likelihood was
0.358. The cost per NRI was $615 for the stress MPS as compared with an exercise test.
CONC L U S I O N S Stress-induced ischemia is independently predictive of near-term CAD outcomes.
Analytical approaches that establish the reclassiﬁcation of events provide a unique approach and may
serve as a quality imaging metric for estimation of improved health outcomes for stress MPS as well as
for comparison to other imaging modalities. (J Am Coll Cardiol Img 2010;3:1139–48) © 2010 by the
American College of Cardiology Foundation
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1140he concept of risk stratification using clin-
ical and laboratory markers has been a major
focus of observational registries over the past
several decades. Risk prediction that inte-
rates clinical variables into a prognostic model
esults in the identification of cardiac risk factors
ith a, generally, graded impact on prognosis (1,2).
he development of a prognostic model tradition-
lly includes the evaluation of the independent
ontribution of variables with consideration of co-
arying factors that may confound risk stratification
3). Yet, the multivariable modeling process fails to
efine how a given risk marker improves the clas-
ification of risk, that is, the enhanced detection of
ow- or high-risk patients. Improvements in dis-
rimination may be accomplished using receiver-
perator characteristic (ROC) curves, yet they fail
o quantify the proportion of patients and the
direction of improvement in classifying
low- to high-risk patients. Risk reclassifi-
cation methods that enumerate newly de-
fined patient subsets have clinical appeal
and an ease of understanding where other
analytical approaches do not.
Few reports have explored the compar-
ative ability of stress myocardial perfusion
single-photon emission computed tomog-
raphy (MPS) risk markers using varied
iterative, incremental, and risk classifica-
tion approaches (4,5). The aim of the
current study was to estimate coronary
artery disease (CAD) death or myocardial
infarction (MI) using traditional ap-
proaches of prognostication to more recent
methods from a large prospective registry of
table chest pain patients undergoing stress MPS,
ocusing on improved risk detection with ischemia as
ompared with electrocardiographic and pre-test like-
ihood measurements (6–8).
E T H O D S
he methods of the Myoview Prognosis Registry
ere previously published (6–8). Of the 7,849
atients enrolled, 4,575 patients had rest and post-
tress left ventricular ejection fraction (LVEF) and
PS. Study procedures were approved by each
enter’s institutional review board.
tress testing protocols. Forty percent of patients
nderwent exercise testing using the modified
ruce protocol. Heart rate, blood pressure, and
lectrocardiographic changes were monitored.
se
ionesting was discontinued at maximal stress, fatigue, Cr due to:3 mm of ST-segment depression or1
m of ST-segment elevation (in a non–Q-wave
ead); ventricular tachycardia or fibrillation; exer-
ional hypotension, chronotropic incompetence, or
orsening chest pain. The remaining patients un-
erwent pharmacologic stress; with monitoring
rocedures similar to exercise testing.
est and stress gated MPS. Each scan was inter-
reted by a nuclear cardiologist blinded to the
atient’s stress test and clinical data. However,
he patient’s sex was accessible to the interpreter.
PS procedures were standardized across partici-
ating sites (9). Patients underwent either rest
l-201 or Tc-99m. Representative short-axis and
orizontal long-axis images were segmented into 20
egions for interpretation of myocardial perfusion.
ach segment was scored from normal uptake
score  0) to absent perfusion (score  4). Total
cores at rest and post-stress were summed. To
efine percentage ischemic myocardium, the total
tress score was subtracted from the total rest score
nd divided by 80 to get the percentage ischemic
yocardium.
ollow-up methodologies. Patients were prospec-
ively followed using a scripted interview performed
ver the telephone or during clinic visits; 1% of
atients were lost. Outcome data collection in-
luded documentation of coronary revascularization
rocedures. Death information was confirmed by
eview of the patient’s death certificate or medical
ecords. Fatal MI was defined for patients who died
n-hospital within 24 h of admission following
nzyme elevation. Patients with end-stage CAD
ith heart failure noted as a cause of death were
oded as CAD deaths. A witnessed sudden cardiac
eath was coded as CAD death. Median follow-up
ime for surviving patients was 1.6 years (25th to
5th percentile  1.2 to 2.0 years).
tatistical analyses. Categorical comparisons were
alculated using the chi-square statistic, whereas
ontinuous measures were compared using the non-
arametric Kruskal-Wallis statistic. Time to CAD
eath or MI was estimated using Cox proportional
azard models. Patients were censored at the time
f revascularization or at the time of a primary end
oint, whichever occurred first. Models were ana-
yzed for univariable associations as well as multi-
ariable associations. Model overfitting procedures
ere considered, and the proportional hazards as-
umption was met.
For the risk-adjusted model, we a priori included
ge, sex, risk factors, symptoms, stress type, andB B R E V I A T I O N S
N D A C R O N YM S
AD coronary artery disea
V cardiovascular
TS Duke Treadmill Score
VEF left ventricular eject
raction
Imyocardial infarction
PSmyocardial perfusion
ingle-photon emission
omputed tomography
RI net reclassification
mprovement
OC receiver-operatorAD history as covariates. The proportion of
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1141xcess risk explained was calculated using the equa-
ion: [HRUHRA] / [HRU 1], where HR is the
azard ratio, HRU is an unadjusted HR, and HRA
s a risk-adjusted HR (10).
Additional models, which examined the incre-
ental value of stress MPS variables of LVEF and
schemia, were calculated by defining unadjusted
odels followed by additional models including:
) age and sex adjustment; 2) age, sex, CAD history,
tress type, and cardiac symptom adjustment; and
) age, sex, CAD history, cardiac symptoms, stress
ype, and cardiac risk factors. The ROC curve areas
95% confidence intervals [CI]) were calculated.
We then applied the reclassification methodolo-
ies of Pencina et al. (11,12). We compared: 1) the
ddition of the Duke Treadmill Score (DTS) in a
odel including the CAD likelihood; and 2) the
ddition of the MPS ischemia in a model including
he DTS. We applied risk categories of1%, 1% to
%, 3.01% to 5.00%, and 5% predicted CAD
eath or MI rate per year. For those with events, the
umber reclassified upward and those reclassified
ownward was enumerated, followed by a subtraction
f the number with events upwardly reclassified minus
hose downwardly reclassified, then divided by the
otal number of events. For those without events, the
otal number who were classified upwards and those
eclassified downward was enumerated, followed by a
ubtraction of patients without events downwardly
eclassified minus those upwardly reclassified, then
ivided by the total number of nonevent patients. The
et reclassification improvement (NRI) was then cal-
ulated by summing the calculations from these latter
sentences (13).
We calculated the incremental costs of: 1) exer-
ise test–outpatient visit; and 2) MPS–exercise test.
rocedural costs were applied to estimate cost per
RI (14,15). Procedural costs were determined
rom the 2010 Medicare Physician Fee Schedule for
urrent Procedural Terminology (CPT) codes
3015 and 78452 (16) and from the Medicare
utpatient PC Pricer System using APC code 601
or a midlevel clinic visit (17).
E S U L T S
linical characteristics of theMyoview Prognosis Registry.
atients were typical of those referred to a stress
maging laboratory (Table 1). They were on average
2 years of age, mostly male, with the majority
eferred for evaluation of stable chest pain
ymptoms. rThe stress MPS results (Table 2) reveal that the
ajority of patients underwent pharmacologic
tress or exercised through stage II of the modified
ruce protocol. ST-segment depression 1 mm
ccurred frequently in this cohort (range  32% to
8%). Approximately 9% to 20% of low- to high-
ikelihood patients had ischemia 5% of the myo-
ardium. Few patients had rest or stress LVEF
45%; except 13% to 15% of high-likelihood
atients had LVEF measures 45%. We present
lood pressure data on the whole cohort; higher
esting systolic blood pressure was reported with
harmacologic stress (mean: 146 mm Hg for phar-
acologic stress vs. 136 mm Hg for exercise),
hereas higher peak exercise systolic blood pressure
as reported with peak exercise (mean: 187 mm Hg
or exercise vs. 158 mm Hg for pharmacologic
tress).
ox survival curves estimating time to CAD death or MI.
n risk-adjusted models, stress MPS ischemia (p 
.0001), rest (p  0.0001), and post-stress LVEF
p  0.0001) were significant estimators of time to
AD death or MI (Fig. 1).
rognostic models estimating mortality with stress
PS ischemia and LVEF. Table 3 depicts a multiva-
Table 1. Clinical Descriptors of the Myoview
Prognosis Registry
n  4,575
Age (median, 25th, 75th percentile), yrs 62 (56, 70)
Female sex 37%
Chest pain symptoms
No chest pain 21%
Nonanginal or atypical chest pain 22%
Typical angina 38%
Heart failure symptoms 7%
Prior revascularization
Percutaneous coronary intervention 13%
Coronary bypass graft surgery 14%
History of CAD 32%
Number of cardiac risk factors
0 24%
1–2 56%
3 20%
Current cigarette smoking 27%
Family history of CAD 31%
Hypertension 54%
Hyperlipidemia 43%
Diabetes mellitus
Noninsulin dependent 14%
Insulin dependent 9%
CAD  coronary artery disease.iable model including all 3 MPS variables, noting
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1142hat all were highly significant estimators of death
r MI, even in adjusted models that included an
rray of symptom, risk factor, and historical vari-
bles. The multivariable HRs for CAD death or MI
ere 1.6 (95% CI: 1.3 to 2.0), 1.5 (95% CI: 1.2 to
.9), and 2.0 (95% CI: 1.6 to 2.4) for rest LVEF
45%, post-stress LVEF 45%, and stress perfu-
ion ischemia 5% of the myocardium, respectively
each p  0.0001). Significant collinearity did not
xist among the 3 variables (r  0.5). Interestingly,
n a subset analysis of patients with diabetes, the
Rs were similar (MPS ischemia: 2.0, p 0.0001);
est LVEF: 1.5, p  0.009), with the exception
ost-stress LVEF was of borderline significance
HR: 1.4, 95% CI: 1.0 to 1.9; p  0.05).
In stepwise models including age, sex, presenting
ymptoms, stress type, risk factors, and CAD his-
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Rest LVEF
(p<0.0001)0.0
0.2
0.4
0.6
0.8
1.0
0.0 1.0 2.0
45% (n=4,158)
<45% (n=417)
Follow-up (Years
Post-Stress
(p<0.0001)0.0
0.2
0.4
0.6
0.8
1.0
0.0 1.0
Figure 1. Cox Risk-Adjusted Cardiac Event-Free Survival by Rest
Table 2. Stress Imaging Results by CAD Pre-Test Likelihood
Low
(n  902)
Pharmacologic stress 64%
Resting ST-T wave changes 29%
Heart rate
Rest 71 13
Peak exercise 133 37
Systolic blood pressure
Rest 142 24
Peak stress 172 37
Diastolic blood pressure
Rest 79 17
Peak exercise 79 17
Exertional chest pain 7%
ST-segment depression 1.0 mm 38%
Exercise time 9.1 3
MPS 5% ischemic myocardium 9%
LVEF
Rest 45% 4%
Post-stress 45% 4%
CAD  coronary artery disease; LVEF  left ventricular ejection fraction; MPS Losses to follow-up in years 1 and 2 were 4.3% and 16.3%. LVEF  leftory as well as the 3 MPS variables, ischemia was
anked first whereas rest LVEF 45% was ranked
econd and post-stress LVEF 45% was ranked
ighth. Factors chosen before post-stress LVEF
ncluded anginal symptoms, smoking, diabetes, age,
nd hypertension.
ncrement value analyses. When comparing the rel-
tive contribution of each MPS variable to the
eath or MI models, the total percentage contribu-
ion was greatest for stress ischemia, yielding 34%
f prognostic content (Fig. 2). That is, when
onsidering the estimation of risk with age, sex, risk
actors, presenting symptoms, CAD history, and
tress type, 34% of the chi-square was contributed
y ischemia.
Unadjusted and risk-adjusted HRs are presented
or rest and post-stress LVEF 45% and 5%
45% (n=4,159)
<45% (n=416)
Cu
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c 
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e 
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iv
al
Follow-up (Years)
Stress Ischemia
(p<0.0001)0.0
0.2
0.4
0.6
0.8
1.0
0.0 1.0 2.0
<5% Myocardium (n=4,239)
5% Myocardium (n=336)
d Post-Stress LVEF and Stress Ischemia
CAD Pre-Test Likelihood
Intermediate
(n  1,564)
High
(n  2,837) p Value
49% 59% 0.0001
28% 44% 0.0001
71 15 68 13 0.0001
137 33 119 34 0.0001
140 22 144 23 0.0001
176 36 164 43 0.0001
80 15 78 14 0.0001
81 15 77 14 0.0001
13% 14% 0.0001
36% 32% 0.001
8.8 3 9.1 3 0.093
15% 20% 0.0001
5% 15% 0.0001
7% 13% 0.0001
ocardial perfusion single-photon emission computed tomography.)
2.0
anventricular ejection fraction.
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1143schemic myocardium (all p 0.0001). In Figure 3,
nadjusted hazards ranged from 2.3 to 2.5. In
odels estimating CAD death or MI, the propor-
ion of excess risk explained by clinical factors was
inimal (4.5%) for stress ischemia, whereas excess
isk estimates were in the range of 33% to 35% for
VEF; supporting a strong independent contribu-
ion of ischemia to prognostic models estimating
AD death or MI.
OC curve areas. Despite being significant in the
isk-adjusted models, the ability of each MPS
arker to classify CAD death or MI varied (Table 4).
reas under the ROC curve were 0.61 for pre-test
AD likelihood; when adding rest and post-stress
VEF measurements, this increased to 0.66 and to
.69 when adding stress MPS (p  0.0001).
RI of 2-year death or MI. The NRI was 0.112 when
he DTS was added to a model containing CAD
ikelihood (Table 5). Further, the NRI was 0.358
hen MPS ischemia was added to a model con-
aining the DTS and CAD likelihood. In the latter
odel including MPS, newly identified cases (i.e.,
vents upwardly classified) more often underwent
harmacologic stress imaging (82.1%), were at
ntermediate-high pre-test CAD likelihood
75.5%), or had an intermediate DTS (89.3%).
ewly identified controls (i.e., nonevents down-
ardly classified) more often underwent exercise
M
od
el
 C
hi
-S
qu
ar
e
Ischemia
0
8.7%
34.6%
23.3%
50
100
150
200
250
300
350
400
450
Unadjusted
Age, Gender + Add Cardiac History
Add A
Age, G
Figure 2. Incremental Cox Proportional Hazards Modeling
Incremental Cox proportional hazards modeling estimating time to
age, gender, symptoms, type of stress, cardiac history, and cardiac
Model #2: adjusted for age and sex; Model #3: adjusted for age, sex
and Model #4: adjusted for age, sex, history of coronary disease, ca
age at the top of each column is the relative contribution of gated
(SPECT) variables to the total model chi-square. The calculation is m
risk marker. For example, for ischemia, the addition of age, sex, and
for rest and post-stress left ventricular ejection fraction (LVEF), 34.0%
sex, and cardiac history. In the farthest column, clinical and stress typeesting (41.6%), had 0 to 1 cardiac risk factors
56.1%), and did not have angina as a presenting
ymptom (89.8%). Figure 4 plots the cumulative
requency of exercise times for newly identified
ases and controls, noting higher total exercise
imes with newly defined controls as compared with
ases.
ncremental cost effectiveness analyses. The incre-
ental national payment rate for an exercise test
as an added $6.33 when compared with an out-
atient visit (Table 6). The incremental payment
as $220.20 for MPS when compared with an
xercise test. The cost per NRI was $56.52 for an
xercise test compared with an outpatient visit and
615.08 for a stress MPS as compared with an
xercise test.
t LVEF
%
42.4%
40.0%
Post-Stress LVEF
35.3%
39.7%
33.5%
 Gender
er, Cardiac History + Adding Risk Factors, Stress Type
nary artery disease death or myocardial infarction, adjusting for
factors. Risk-adjusted models include: Model #1: unadjusted;
story of coronary disease, type of stress, and cardiac symptoms;
c symptoms, type of stress, and cardiac risk factors. The percent-
cardial perfusion single-photon emission computed tomography
from each column moving from left to right within each SPECT
diac history provides 8.7% of prognostic content. By comparison,
d 35.3%, respectively, of prognostic content are provided by age,
Table 3. Risk-Adjusted HRs From a Multivariable Model Contain
Post-Stress Measures of LVEF and MPS Ischemia
HR 95% CI Chi-
Rest LVEF 45% 1.63 1.33–2.01
Post-stress LVEF 45% 1.54 1.22–1.94
MPS 5% ischemic myocardium 1.97 1.64–2.38
Model 2  207, p  0.0001. Variables are ordered as the data would be
Unadjusted HRs were 2.59, 2.77, and 2.85 for rest LVEF, post-stress LVEF, a
respectively. Covariate adjustment included: age, sex, risk factors, presenting sy
CAD history. HR  hazard ratio; other abbreviations as in Table 2.Res
34.0
ge &
end
coro
risk
, hi
rdia
myo
ade
car
aning Rest and
Square p Value
21 0.0001
14 0.0001
50 0.0001
available during testing.
nd stress MPS ischemia,
mptoms, stress type, andvariables add 23.3%, 40.0%, and 33.5% of prognostic content.
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1144I S C U S S I O N
remendous growth in cardiac imaging has fostered
umerous policy efforts aimed toward containing
tilization and devising metrics to define quality
ardiovascular (CV) imaging. Recent efforts from
oth public and private payers have focused on
xtending test evaluation criteria beyond that of
raditional performance characteristics (e.g., diag-
ostic sensitivity and specificity) to include mea-
ures defining improvements in health outcome
14,15). The development of quality imaging met-
ics is now paramount for evaluation of a test’s
dded value in order to justify the referral decision.
n an era where health care resources are limited
nd the perception of imaging utilization is that of
xcess, the development of analytical approaches are
mportant to define a test’s “value for money spent”
18). In our report, we evaluated both conventional
H
az
ar
d 
Ra
tio
 (x
-fo
ld)
1.00
2.3-
1.8-
1.25
1.50
1.75
2.00
2.25
2.50
2.75
3.00
Rest LVEF 45%
32.8% reduction
in Hazard Ratio
with clinical
risk-adjustment
Post-S
3
Unadjusted Death or M
Figure 3. Unadjusted and Risk-Adjusted HR for Estimation of CA
This ﬁgure provides data on the extent to which each myocardial p
the column sets includes a separate unadjusted and adjusted progn
and MPS variables p  0.0001. Regression models were adjusted w
presenting symptoms, type of stress, and CAD history. CAD  coro
other abbreviations as in Figure 2.
reas for CAD Event Classiﬁcation by Pre-Test CAD Likelihood
and Post-Stress LVEF and Stress MPS Ischemia
Area 95% CI
Comparative
p Value
0.61 0.59–0.63 —
 rest LVEF 0.65 0.62–0.67 0.026
 rest and post-stress LVEF 0.66 0.64–0.68 0.60
 rest and post-stress LVEF 
myocardium
0.69 0.67–0.72 0.0001tOC  receiver-operator characteristic; other abbreviations as in Table 2.isk stratification methods as well as new innovative
pproaches that may prove valuable to assess a test’s
alue in clinical decision making. Our results reveal
hat beyond near-term risk stratification, important
rends were identified, emphasizing the importance
f stress ischemia as a core measure of risk. Regard-
ess of the analytical approach, 5% or more of
schemic myocardium was an important measure of
stimating 2-year risk of CAD death or MI. In fact,
his measure was effective at reclassifying a sizeable
roportion of patients.
The use of reclassification methods as a novel
arker of a test’s incremental value has appeal
ecause it can be easily performed using available
bservational registries as well as in administrative
atasets. This type of analysis may be one method
o devise net improvement in outcome, a recent
tandard put forth in technology evaluation criteria
14,15). Within recent technology evaluations, the
tandard of improving health outcomes was defined
s a test’s ability to improve the quantity or quality
f patient’s life (14,15). From the epidemiologic
iterature, a new method for devising improved risk
tratification has been proposed (12) that includes
he calculation of net reclassification in risk. Several
eports have noted this as an effective method for
valuating the added value of high sensitivity
-reactive protein beyond that of the Framingham
isk score (12,13,19,20). Although net reclassifica-
-
2.0-
s LVEF 45%
 reduction
zard Ratio
 clinical
djustment
2.5-
2.5-
Stress Ischemia 5 %
Myocardium
4.5% reduction
in Hazard Ratio
with clinical
risk-adjustment
Adjusted Death or MI
eath or MI
sion SPECT risk marker is attenuated by clinical covariates. Each of
ic model for each of the LVEF and ischemia variables. All models
he following clinical covariates: age, gender, cardiac risk factors,
artery disease; HR  hazard ratio; MI  myocardial infarction;2.5
tres
4.9%
in Ha
with
risk-a
I
D D
erfu
ost
ith t
naryTable 4. ROC Curve A
Combined With Rest
Pre-test CAD likelihood
Pre-test CAD likelihood
Pre-test CAD likelihood
Pre-test CAD likelihood
stress MPS ischemicion in risk has been applied in the setting of CV
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1145creening of apparently healthy individuals (19,20),
rior reports have not utilized this analytical ap-
roach for the evaluation of risk in symptomatic
atients. With the incorporation of net reclassifica-
ion of risk, we propose that this may be one
ethodology to evaluate a test’s ability to note
mprovements in outcome detection beyond the
re-test risk evaluation.
ncremental cost effectiveness analyses. Using this
pproach, should the test reclassify few patients,
hen its value would be minimal. Conversely,
hould a test reclassify a sizeable proportion of
atients, then the cost of the procedure may be
ustified. We devised a simple cost model to exam-
ne the impact of NRI as a novel effectiveness
easure. In this report, exercise testing was roughly
imilar in cost to an outpatient visit but newly
eclassified nearly 11% of patients using risk data
Table 5. Calculations of the NRI Evaluating the Addition of the
Model With the Pre-test CAD Likelihood and DTS
A. Estimation of CAD Death or MI After DTS In
Estimation of CAD Death
or MI by Pre-Test CAD
Likelihood
Estimati
<1% 1–3%
<1% 6 14 0
1–3% 17 510 10 26
3–5% 1 4 25 58
>5% 0 0 6 11
Total 24 528 41 96
Steps in Calculation:
I. Patients Experiencing CAD Death or MI: 0 patients were reclass
reclassiﬁed downwards
Net % classiﬁed  (0  78)/234  33.3%
II. Patients Not Experiencing a CAD Death or MI: 1,933 (510  4
patients reclassiﬁed upward
Net % classiﬁed  (1,933  0)/4,341  44.5%
III. NRI  (33.3%  44.5%)  11.2% (p  0.001)
B. Estimation of CAD Death or MI After MPS In
Estimation of CAD Death
or MI by Pre-Test CAD
Likelihood and DTS
Estimatio
<1% 1–3%
<1% 15 187 6 3
1–3% 11 374 28 55
3–5% 0 1 9 63
>5% 0 0 6 10
Total 26 562 48 1,33
Steps in Calculation:
I. Patients Experiencing CAD Death or MI: 37 (6  1  8  0 
 6  17) patients were reclassiﬁed downwards
Net % classiﬁed  (37  42)/234  2.5%
II. Patients Not Experiencing a CAD Death or MI: 1,878 (374  1
2  65  0  27  88) patients reclassiﬁed upward
Net % classiﬁed  (1,878  217)/4,341  38.3%
III. NRI  (2.5%  38.3%)  35.8% (p  0.001).
Each cell includes the number of cases (regular font) and noncases (boldcase f
DTS  Duke Treadmill Score; NRI  net reclassiﬁcation improvement; other arom the DTS, resulting in a cost per NRI of $57 chen compared with an outpatient visit. There are
o metrics or league tables for this novel cost-
ffectiveness metric, yet these analyses may provide
venue for evaluating value or discerning appropri-
te utilization of clinical resources. For the exercise
est, it is clear that the cost per NRI of $57 is low
nd is far less than that for a midlevel clinic visit.
owever, stress MPS cost more than $200 but did
o within the context of reclassifying nearly one-
hird of patients; resulting in a cost per NRI of
$615 when compared with an exercise test. It
emains challenging to interpret this value, but
hen compared with stress echocardiography (a
heaper modality), the NRI would only have to be
0.3% (given a 2010 Medicare payment rate of
203) in order to achieve a cost per NRI of $615.
oreover, if the NRI for stress echocardiography
as similar to that of MPS (i.e., 35.8%), then the
to a Model With the Pre-Test CAD Likelihood and MPS to a
ded in a Model with Pre-Test CAD Likelihood
f CAD Death or MI After DTS Included
3–5% >5% Total
0 0 0 0 6 14
0 0 0 0 27 772
4 90 0 0 30 680
29 716 136 2,041 171 2,875
33 806 136 2,041 234 4,341
upwards and 78 (17  1  0  25  6  29) patients were
 586  118  716) patients reclassiﬁed downward and 0
ded in a Model with DTS and CAD Likelihood
f CAD Death or MI After MPS Included
3–5% >5% Total
1 2 0 0 22 224
8 65 6 27 53 1,022
7 195 15 88 31 921
17 757 106 1,308 129 2,174
33 1,019 127 1,423 234 4,341
15) patients were reclassiﬁed upwards and 42 (11  0  0  9
37  109  757) patients reclassiﬁed downward and 217 (35 
viations as in Table 2.DTS
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1146nclusion of induced costs is paramount to further
evelopment of this novel cost effectiveness metric.
oreover, employing the calculation of cost per
RI in diverse patient populations and across
ultiple modalities would help to validate this
etric and to define a league table of comparative
ost-effectiveness measures. The result could be a
imple measure that may be applied to guide fo-
used resource utilization.
Many have argued that reliance upon standard
ost-effectiveness measures of cost per life-year
aved fits more within therapeutic strategies and
hat testing does not save a life but rather detects
isk. Any given test only indirectly impacts out-
ome, with the ensuing treatment saving lives. Of
ourse, this latter statement remains controversial
nd is the subject of ongoing discussions regarding
AD imaging. Importantly, randomized trials eval-
ating the comparative effectiveness, including dis-
erning the economic value of testing versus non-
esting strategies, are an important part of ongoing
iscussions on developing broader, high-quality
Exercise Time (in Minutes)
2 4 6 8 10 12 14 16
Newly Identified by MPS:
Controls
Cases
Frequency Distribution for Newly Identiﬁed Cases and Controls
culation
hat newly identiﬁed controls (i.e., low-risk, event-free survivors)
exercise times. Conversely, newly identiﬁed cases (i.e., high risk
ften had lower exercise times. Patients with a 0 exercise time
rgoing pharmacologic stress imaging. MPS  myocardial perfu-
ission computed tomography; NRI  net reclassiﬁcation
Table 6. Incremental Cost per NRI
Exercise test for calculation of DTS vs. outpatient
visit for assessment of CAD likelihood
Stress MPS vs. exercise test for calculation of DTSAbbreviations as in Table 5.vidence with CAD testing. As well, the inclusion
f more than just procedural cost data would
rovide greater improvement in creating value and
fficiency for noninvasive testing.
ovarying risk markers and estimating imaging risk.
ew prior reports have examined the gamut of
nalysis presented herein. From our analyses, it is
ow apparent that much of the estimated CV risk
rom an imaging risk marker overlaps with cardiac
istory and comorbidity (1,19–22). Nearly one-
hird of risk was encumbered by clinical covariates
nown prior to the stress MPS. Similarly, in a
ull-risk model, stress ischemia provided 34.2% of
ovel information content. This sizeable influence
f pre-test cardiac risk, unless accounted for analyt-
cally, will result in an inflated value of any test. In
his large registry, post-stress LVEF ranked below
everal historical factors including angina, smoking,
nd diabetes. This further illustrates the importance
f a unified analytical approach to assessing a test’s
dded value. The relative contribution of stress
PS variables in stepwise modeling reveal that
mprovement in risk prediction remains possible,
specially when tailored to disease-specific effects of
ging or diabetes or symptom stability and fre-
uency, as may be the case with new metabolic or
olecular imaging agents (23–30).
tudy limitations. We attempted to use strict criteria
or classification of death; however, it remains that
proportion of all-cause deaths may be CAD in
rigin (31). Patients’ lost during follow-up had a
imilar clinical risk profile as compared with the
ncluded cohort. The inclusion of other variables,
uch as transient ischemic dilation and increased
ung uptake, may alter our presented results but
ere not uniformly available. Finally, a longer time
eriod for follow-up may have revealed varying
esults than those presented herein.
O N C L U S I O N S
remendous growth in cardiac imaging has fostered
umerous policy efforts aimed toward containing
tilization and devising metrics to define quality
Incremental Cost Cost/NRI
8.63 $72.30 $6.33 $6.33/0.112 $56.52
8.83 $78.63 $220.20 $220.20/0.358 $615.08Cu
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1147V imaging. The development of quality imaging
etrics is now paramount for evaluation of a test’s
dded value in order to justify the referral decision.
n the current report, we evaluated both conven-
ional risk stratification methods as well as new
nnovative approaches that may prove valuable to
ssess a test’s value in clinical decision making. Our
esults reveal that many patients may be risk reclas-
ified and that this analytical method may prove
seful for assessing a test’s impact on health out-
omes. Although comparative data are not available
or other imaging modalities, the development of a
eague table of net reclassification indexes across
odalities may prove useful for evaluation of com-Prognostic value of normal exercise
Disease. Rockville,
Healthcare Researay prove useful for evaluating referral decisions.
iven that not all evidence may be derived from
arge clinical trials, strategies need to be devised to
valuate “real world” effectiveness. The evaluation
f risk reclassification may serve as 1 measure for
valuation of large administrative databases or for
egistry purposes. (2,11).
eprint requests and correspondence: Dr. Leslee J. Shaw,
256 Briarcliff Rd NE, Suite 1-N, Emory University
chool of Medicine, Atlanta, Georgia 30306. E-mail:arative effectiveness. Moreover, the cost per NRI leslee.shaw@emory.edu.1
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